Distribution, compliance, and efficiency trends powering cannabis supply networks.
UK medical cannabis patients have been told that they’ll have access to a six-month stockpile of Bedrolite, following weeks of uncertainty in the wake of Bedrocan’s collapse.
A Michigan breach-of-contract dispute between cultivator Hello Farms and Curaleaf Holdings has cracked open a fault line that runs beneath every cannabis contract in the US, opening the door to a ‘mutually assured destruction’ defence that cannot be closed.
This article was originally published in February 2026, and was most recently updated on September 22, 2026.
Written by Michael Sassano, Founder and Interim CEO, SOMAÍ Pharmaceuticals Most US cannabis companies thinking about Europe focus on the wrong number.
Israel’s Ministry of Economy and Industry has already reopened its anti-dumping investigation into Canadian medical cannabis, just a week after a procedural defect forced the same case to close.
New Zealand-listed Rua Bioscience (NZX: RUA) has agreed a sales and distribution deal with one of the UK’s largest medicinal cannabis clinic and distribution businesses, expected to generate NZ$10m in revenue over two years, the company’s largest export contract to date.
Authorities from the German state of Hesse have taken aim at the practice of ‘GMP washing’ in its thriving medical cannabis market, an intervention that could have significant implications for the industry at large.
Last year (fiscal year 2024/2025), Canada’s legal cannabis industry recorded revenues of CA$5.5bn, according to the latest figures from Statistics Canada.
Written by Oskar Fletcher, Chief Executive of pharmaceutical contract manufacturing operator Blossom Pharma.
